Literature DB >> 12935921

DNA copy number changes detected by comparative genomic hybridization and their association with clinicopathologic parameters in breast tumors.

Sultan Cingoz1, Oguz Altungoz, Tulay Canda, Serdar Saydam, Gazanfer Aksakoglu, Meral Sakizli.   

Abstract

The purpose of this study was to use comparative genomic hybridization (CGH) to screen breast tumors for copy number changes: 22 ductal, 9 lobular, 7 mixed, 2 micropapillary carcinomas, and 2 ductal carcinoma in situ were studied and various regional genomic imbalances were detected. The majority of the aberrations identified in this study were in line with previous CGH findings. The most frequent DNA sequence copy number changes were 1q, 8q, and 20q gains. The frequency of 16q losses was significantly higher in lobular carcinomas. The nodal involvement was 10 times higher in cases showing losses of 13q than in cases having normal peak profile at this region. Estrogen receptor positivity was significantly higher in cases displaying 20q gains and 16q losses. Unambiguous high-level DNA amplifications have also been detected. These mapped to 4q31, 6q21 approximately q22, 8q21 approximately q24, 8p11.2 approximately p12, 11q13, 15q24 approximately qter, 20q13.1 approximately qter, and 20q12 approximately qter chromosomal locations. Our results highlight several chromosomal regions that may be important in the molecular genetics of distinct clinicopathologic breast cancer subgroups.

Entities:  

Mesh:

Year:  2003        PMID: 12935921     DOI: 10.1016/s0165-4608(03)00094-3

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

Review 1.  The changing role of pathology in breast cancer diagnosis and treatment.

Authors:  Anthony S-Y Leong; Zhengping Zhuang
Journal:  Pathobiology       Date:  2011-06-14       Impact factor: 4.342

2.  Haploinsufficiency in the prometastasis Kiss1 receptor Gpr54 delays breast tumor initiation, progression, and lung metastasis.

Authors:  Sung-Gook Cho; Ying Wang; Melissa Rodriguez; Kunrong Tan; Wenzheng Zhang; Jian Luo; Dali Li; Mingyao Liu
Journal:  Cancer Res       Date:  2011-08-18       Impact factor: 12.701

3.  Genetic variants in the 8q24 locus and risk of testicular germ cell tumors.

Authors:  Michael B Cook; Barry I Graubard; Sabah M Quraishi; Meredith Yeager; Stephen J Chanock; Andrew Crenshaw; Ralph L Erickson; Mark V Rubertone; Gilles Thomas; Katherine A McGlynn
Journal:  Hum Genet       Date:  2008-03-29       Impact factor: 4.132

4.  Significance of genomic instability in breast cancer in atomic bomb survivors: analysis of microarray-comparative genomic hybridization.

Authors:  Masahiro Oikawa; Koh-ichiro Yoshiura; Hisayoshi Kondo; Shiro Miura; Takeshi Nagayasu; Masahiro Nakashima
Journal:  Radiat Oncol       Date:  2011-12-07       Impact factor: 3.481

5.  Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers.

Authors:  Erhan Bilal; Kristen Vassallo; Deborah Toppmeyer; Nicola Barnard; Inga H Rye; Vanessa Almendro; Hege Russnes; Anne-Lise Børresen-Dale; Arnold J Levine; Gyan Bhanot; Shridar Ganesan
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

Review 6.  Array-CGH and breast cancer.

Authors:  Erik H van Beers; Petra M Nederlof
Journal:  Breast Cancer Res       Date:  2006-06-30       Impact factor: 6.466

7.  Gene expression profiling of the 8q22-24 position in human breast cancer: TSPYL5, MTDH, ATAD2 and CCNE2 genes are implicated in oncogenesis, while WISP1 and EXT1 genes may predict a risk of metastasis.

Authors:  Afsoon Taghavi; Mohammad Esmaeil Akbari; Mohammad Hashemi-Bahremani; Nahid Nafissi; Ahad Khalilnezhad; Seyed Mohammad Poorhosseini; Feyzollah Hashemi-Gorji; Vahid Reza Yassaee
Journal:  Oncol Lett       Date:  2016-09-30       Impact factor: 2.967

8.  Gene Expression Meta-Analysis Identifies Cytokine Pathways and 5q Aberrations Involved in Metastasis of ERBB2 Amplified and Basal Breast Cancer.

Authors:  Mads Thomassen; Qihua Tan; Mark Burton; Torben A Kruse
Journal:  Cancer Inform       Date:  2013-11-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.